Bevacizumab-800CW targets vascular endothelial growth factor A (VEGF-A) and is a promising tracer, since it is overexpressed in PitNETs with CS invasion [13], lactotroph PitNETs, and pituitary carcinomas [14–17]. This evidence concerns the gene VEGFA and pituitary adenocarcinoma.